Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Triamcinolone in the Treatment of Psoriasis

Triamcinolone in the Treatment of Psoriasis Abstract Treatment of uncomplicated psoriasis with steroids in general is unsatisfactory.1,2 Recently, however, a new corticosteroid, triamcinolone,* has been marketed and from clinical trials appears to have a dramatic effect in relatively low doses.3-5 This remarkable observation prompted us to investigate the drug in a group of psoriatics under rigid experimental conditions. Methods Thirty-four patients with uncomplicated but recalcitrant psoriasis of 10 or more years' duration volunteered to be subjects.† The experimental plan called for one group to receive 4 mg. four times a day for a month; a second group, 4 mg. daily, and a third group, a placebo. All other therapy was discontinued. At the end of one month, the treatment schedule was arbitrarily changed. At random, some patients received 8 mg. daily, some a placebo, and some nothing. In the third month, all treatment was stopped and follow-up observations were made. The subjects References 1. The triamcinolone was supplied through the courtesy of Dr. John T. Groel, Associate Medical Director , The Squibb Institute, New Brunswick, N. J. 2. The National Psoriasis Research Association (Diane Mullins, Pres.) cooperated in contacting potential subjects. 3. Fergusson, G. A., and Dewar, W. A.: Observations on Steroid Therapy in Psoriasis , Brit. J. Dermat. 69:57-60 ( (Feb.) ) 1957.Crossref 4. Editorial Comments , in The Year Book of Dermatology and Syphilology (1957-1958 Year Book Series) edited by R. L. Baer and V. H. Witten, Chicago, The Year Book Publishers, Inc., 1958, pp. 47-48. 5. Hollander, J. L.; Brown, E. M.; Jessar, R. A.; Smukler, N. M.; Udell, L.; Shanahan, J. R.; Stevenson, C. R., and Bowie, M. A.: The Effect of Triamcinolone on Psoriatic Arthritis , presented before the American Rheumatism Association, Bethesda, Md., Dec. 6, 1957. 6. Goldberg, L.: A Short Summary of My Experience with Medrol, The Schock Letter (May) 1958. 7. Shelley, W. B.; Harun, J. S., and Pillsbury, D. M.: The Treatment of Psoriasis and Other Dermatoses with Triamcinolone (Aristocort) , J. A. M. A. 167:959-964, 1958.Crossref 8. Henneman, P. H.; Wang, D. M. K.; Irwin, J. W., and Burrage, W. S.: Syndrome Following Abrupt Cessation of Prolonged Cortisone Therapy , J. A. M. A. 158:384-386, 1955.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png A.M.A. Archives of Dermatology American Medical Association

Triamcinolone in the Treatment of Psoriasis

Loading next page...
 
/lp/american-medical-association/triamcinolone-in-the-treatment-of-psoriasis-isaBO2y0yk
Publisher
American Medical Association
Copyright
Copyright © 1959 American Medical Association. All Rights Reserved.
ISSN
0096-5359
DOI
10.1001/archderm.1959.01560150092014
Publisher site
See Article on Publisher Site

Abstract

Abstract Treatment of uncomplicated psoriasis with steroids in general is unsatisfactory.1,2 Recently, however, a new corticosteroid, triamcinolone,* has been marketed and from clinical trials appears to have a dramatic effect in relatively low doses.3-5 This remarkable observation prompted us to investigate the drug in a group of psoriatics under rigid experimental conditions. Methods Thirty-four patients with uncomplicated but recalcitrant psoriasis of 10 or more years' duration volunteered to be subjects.† The experimental plan called for one group to receive 4 mg. four times a day for a month; a second group, 4 mg. daily, and a third group, a placebo. All other therapy was discontinued. At the end of one month, the treatment schedule was arbitrarily changed. At random, some patients received 8 mg. daily, some a placebo, and some nothing. In the third month, all treatment was stopped and follow-up observations were made. The subjects References 1. The triamcinolone was supplied through the courtesy of Dr. John T. Groel, Associate Medical Director , The Squibb Institute, New Brunswick, N. J. 2. The National Psoriasis Research Association (Diane Mullins, Pres.) cooperated in contacting potential subjects. 3. Fergusson, G. A., and Dewar, W. A.: Observations on Steroid Therapy in Psoriasis , Brit. J. Dermat. 69:57-60 ( (Feb.) ) 1957.Crossref 4. Editorial Comments , in The Year Book of Dermatology and Syphilology (1957-1958 Year Book Series) edited by R. L. Baer and V. H. Witten, Chicago, The Year Book Publishers, Inc., 1958, pp. 47-48. 5. Hollander, J. L.; Brown, E. M.; Jessar, R. A.; Smukler, N. M.; Udell, L.; Shanahan, J. R.; Stevenson, C. R., and Bowie, M. A.: The Effect of Triamcinolone on Psoriatic Arthritis , presented before the American Rheumatism Association, Bethesda, Md., Dec. 6, 1957. 6. Goldberg, L.: A Short Summary of My Experience with Medrol, The Schock Letter (May) 1958. 7. Shelley, W. B.; Harun, J. S., and Pillsbury, D. M.: The Treatment of Psoriasis and Other Dermatoses with Triamcinolone (Aristocort) , J. A. M. A. 167:959-964, 1958.Crossref 8. Henneman, P. H.; Wang, D. M. K.; Irwin, J. W., and Burrage, W. S.: Syndrome Following Abrupt Cessation of Prolonged Cortisone Therapy , J. A. M. A. 158:384-386, 1955.Crossref

Journal

A.M.A. Archives of DermatologyAmerican Medical Association

Published: Mar 1, 1959

References